Universities decry Biden’s plan for ‘march-in’ rights as disincentivizing biopharma partnerships

A group of non­prof­its rep­re­sent­ing ma­jor aca­d­e­m­ic in­sti­tu­tions and med­ical schools has come out against Pres­i­dent Joe Biden’s new frame­work to use “march-in” rights to re­duce the price of some med­i­cines de­vel­oped with fed­er­al funds.

Echo­ing com­ments from in­dus­try groups like PhRMA, the as­so­ci­a­tions and non­prof­its ar­gued that the frame­work from De­cem­ber in­creas­es un­cer­tain­ty around when march-in rights might be con­sid­ered, “which will have a detri­men­tal and desta­bi­liz­ing ef­fect on uni­ver­si­ty and med­ical school tech­nol­o­gy trans­fer ef­forts and plan­ning.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.